A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients

Trastuzumab has been widely used among the breast cancer patients with human epidermal growth factor receptor 2 (HER2) overexpression. The genetically engineered trastuzumab traded as Cipterbin® was developed in China since 2003. We have disclosed the phase I clinical trial data of safety, pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xinna, Yu, Jing, Wang, Wenmiao, Song, Guohong, Wang, Xiaoli, Ren, Jun, Di, Lijun, Wang, Xinghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688281/
https://www.ncbi.nlm.nih.gov/pubmed/26702392
http://dx.doi.org/10.1186/s40064-015-1603-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688281/
https://www.ncbi.nlm.nih.gov/pubmed/26702392
http://dx.doi.org/10.1186/s40064-015-1603-5

Ejemplares similares